key: cord-0858078-ybjaksct
authors: Hippensteel, Joseph A.; Burnham, Ellen L.; Jolley, Sarah E.
title: Prevalence of Venous Thromboembolism in Critically Ill Patients with COVID‐19
date: 2020-06-02
journal: Br J Haematol
DOI: 10.1111/bjh.16908
sha: c24d510694dd6613b482160702e06ed1b7528c36
doc_id: 858078
cord_uid: ybjaksct

COVID‐19, the disease caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), was first reported in January 2020 (1, 2). It has become apparent that coagulopathy is a hallmark of the disease (3, 4). Additionally, thrombotic complications, including venous thromboembolism (VTE), have been reported to occur in 27‐69% of critically ill patients with SARS‐CoV‐2 (5‐9). As a result of these reports and other anecdotal evidence, many critically ill patients are receiving empiric therapeutic anticoagulation. Yet, experts generally recommend against the use of therapeutic anticoagulation prior to the development of VTE or another clinical indication (4, 10, 11).

COVID-19, the disease caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was first reported in January 2020 (1, 2) . It has become apparent that coagulopathy is a hallmark of the disease (3, 4) . Additionally, thrombotic complications, including venous thromboembolism (VTE), have been reported to occur in 27-69% of critically ill patients with SARS-CoV-2 (5) (6) (7) (8) (9) . As a result of these reports and other anecdotal evidence, many critically ill patients are receiving empiric therapeutic anticoagulation. Yet, experts generally recommend against the use of therapeutic anticoagulation prior to the development of VTE or another clinical indication (4, 10, 11) .

In order to further our understanding of VTE in COVID-19, we evaluated its prevalence as diagnosed through usual care in patients admitted to our intensive care unit (ICU). We also sought to determine the association between a diagnosis of VTE and clinical outcomes. We describe the clinical characteristics of our critically ill patients, frequency of VTE diagnosis, and potential clinical and laboratory predictors of a VTE diagnosis. Last, we performed a multivariate analysis to investigate the association between presence of a VTE diagnosis with mortality.

We performed a retrospective cohort study of critically ill patients with laboratory-confirmed COVID-19 admitted to an academic medical center in Colorado. We included adult patients (age ≥18 years old) who received ICU care. The Colorado Multiple Institutional Review Board approved the study.

Clinical data were abstracted from the electronic health record. Data was last collected on May 6 th , 2020 for all patients. Descriptive statistics were used to analyze continuous and categorical variables. Logistic regression was used to estimate the unadjusted and adjusted associations between presence of VTE and mortality. We included key confounders a priori based on clinical importance in the adjusted model including age, need for invasive mechanical ventilation, need for vasopressors, and presence of any co-existing conditions. All data analyses were performed using STATA software version 13.0 (STATACorp, College Station, TX).

One-hundred and six patients were admitted to the University of Colorado Hospital in Aurora, Colorado between March 18 th and April 14 th , 2020. One patient developed nosocomial SARS-CoV-2

This article is protected by copyright. All rights reserved infection and had been in the hospital since the November of 2019. A total of 107 patients were evaluated for inclusion. Six patients were excluded as they received therapeutic anticoagulation for chronic atrial fibrillation (n = 4), chronic VTE (n = 2), or a mechanical heart valve (n = 1). An additional 11 patients required extracorporeal membrane oxygenation (ECMO) therapy and were analysed separately for VTE presence and excluded from additional analyses. Based upon these exclusions, a total of 91 patients were included in our analyses. VTE was defined by radiographic identification in the routine course of care either by doppler ultrasound of the extremities or computed tomography pulmonary angiography.

Twenty-four patients (26.1%) were found to have VTE during their hospitalization. Of these, 21% (n = 5) were found to have a lower extremity DVT, 25% (n = 6) an upper extremity DVT, 33% (n = 8) an internal jugular thrombus, and 21% (n = 5) pulmonary emboli. In patients who required extracorporeal membrane oxygenation (ECMO) support, 73% developed VTE. Twenty patients (21.7%) without a documented thrombus received therapeutic anticoagulation for suspicion of VTE or clinician concern for hypercoagulability. Six patients received anticoagulation for acute onset atrial fibrillation (n = 4) or an elevated troponin (n = 2). Most patients (54.3%) received therapeutic anticoagulation during their hospitalization.

Characteristics of patients found to have a VTE compared to those without VTE are shown in Table 1 . Patients without a diagnosed were VTE more likely to have a co-existing medical condition (81% vs 58%, p = 0.03). Only three patients had a known underlying malignancy with no known malignancy in the VTE group. Patients with VTE required mechanical ventilation (92 vs 82%) and vasopressors (79 vs 63%) more frequently than non-VTE patients, although these differences were not significantly different. Average creatinine was higher in those with VTE than those without VTE (2.46 vs 1.27, p < 0.05). Average hospital length of stay was significantly longer for patients with VTE than those without VTE (26 vs 16 days, p = 0.001). Other factors known to be associated with VTE including obesity (12) , diabetes mellitus (13) , and smoking (14) were not significantly different between groups.

Patient outcomes and results of univariate and multivariate models examining the association between VTE and mortality are shown in Table 2 . Both groups had comparable rates of extubation, discharge from the ICU, and discharge from the hospital. Patients with VTE were on the ventilator an

This article is protected by copyright. All rights reserved average of 15 days compared to 11 for patients without VTE (p = 0.02). Presence of VTE was not significantly associated with mortality in unadjusted or adjusted analyses. Increasing age and the need for vasopressors were independently associated with increased mortality.

Our findings indicate a high prevalence of VTE in critically ill patients with COVID-19, which are consistent with previous clinical (5-9) and post-mortem reports (15) . As all patients were not routinely screened for VTE, it is likely that our findings underestimate the true prevalence of VTE in this patient population. To our knowledge our report is the second largest investigating this important question. Uniquely, we found that elevated creatinine at time of hospital admission and hospital length of stay were associated with a VTE diagnosis. Patient outcomes were similar for VTE and non-VTE patients in our cohort in contrast to previous reports suggesting worse outcomes amongst patients found to have VTE (6) . This discrepancy may have been related to missed diagnoses of VTE in our cohort and/or inclusion of arterial thrombi (i.e. stroke, myocardial infarction, and other systemic arterial thrombi) in the previous report. Further, the small numbers of overall events in our cohort may have limited our inferences. In conclusion, our findings provide further evidence for a high prevalence of VTE in critically ill patients with SARS-CoV-2 infection. These findings are important for identifying a high risk group for adverse outcomes and to raise clinician awareness of VTE risk amongst critically ill, COVID-19 patients.

We would like to acknowledge all of the front line workers at the University of Colorado Anschutz Medical Campus. JAH and SEJ collected and analysed these data. JAH, ELB, and SEJ designed this research study and wrote this manuscript. 

Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle

A novel coronavirus from patients with pneumonia in China

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

COVID-19 and its implications for thrombosis and anticoagulation

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Obesity as a risk factor in venous thromboembolism

Diabetes mellitus and risk of venous thromboembolism

Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Accepted Article